Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2018;68:394.
Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. The Lancet. 2016;388:73–85.
Chen B-B, Tien Y-W, Chang M-C, Cheng M-F, Chang Y-T, Yang S-H, Wu C-H, Kuo T-C, Shih IL, Yen R-F, Shih T. Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2018;45:1205–17.
Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319.
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245.
Desch AN, Randolph GJ, Murphy K, Gautier EL, Kedl RM, Lahoud MH, Caminschi I, Shortman K, Henson PM, Jakubzick CV. CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell–associated antigen. J Exp Med. 2011;208:1789–97.
Shikhar M, Carolyn DB, Steve C, Elizabeth G-M, Colleen AC, Mingli L, Gina S, Mohamed LS, Michelle HN, Melanie BT, et al. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol. 2017;10:1–13.
Franchi G, Manzoni MF. Cytological Ki-67 in pancreatic endocrine tumors: a new “must”? Gland Surg. 2014;3:219.
Jain R, Fischer S, Serra S, Chetty R. The use of cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol. 2010;18:9.
Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology. 2006;48:674–82.
Zapata M, Cohen C, Siddiqui MT. Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: utility and potential role. CytoJournal. 2007;4:13.
Tamm EP, Silverman PM, Charnsangavej C, Evans DB. Diagnosis, staging, and surveillance of pancreatic cancer. AJR Am J Roentgenol. 2003;180:1311.
Akisik MF, Sandrasegaran K, Bu G, Lin C, Hutchins GD, Chiorean EG. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology. 2010;256:441.
Gerwing M, Herrmann K, Helfen A, Schliemann C, Berdel W, Eisenblätter M, Wildgruber M. The beginning of the end for conventional RECIST—novel therapies require novel imaging approaches. Nat Rev Clin Oncol. 2019;16:442–58.
Larue RTHM, Defraene G, De Ruysscher D, Lambin P, van Elmpt W. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. Br J Radiol. 2017;90:20160665.
Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563.
Aerts HJWL. The potential of radiomic-based phenotyping in precision medicine: a review. JAMA Oncol. 2016;2:1636–42.
Pak L, Gonen M, Seier K, Balachandran V, D’Angelica M, Jarnagin W, Kingham T, Allen P, Do R, Simpson A. Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Abdom Radiol. 2018;43:2113–8.
Eilaghi A, Baig S, Zhang Y, Zhang J, Karanicolas P, Gallinger S, Khalvati F, Haider MA. CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma—a quantitative analysis. BMC Med Imaging. 2017;17:38–38.
Attiyeh M, Chakraborty J, Doussot A, Langdon-Embry L, Mainarich S, Gönen M, Balachandran V, D’Angelica M, DeMatteo R, Jarnagin W, et al. Survival prediction in pancreatic ductal adenocarcinoma by quantitative computed tomography image analysis. Ann Surg Oncol. 2018;25:1034–42.
Haider MA, Vosough A, Khalvati F, Kiss A, Ganeshan B, Bjarnason GA. CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib. Cancer Imaging. 2017;17:4.
Institute for Laboratory Animal Research Institute for Laboratory Animal Research. Guide for the care and use of laboratory animals. 8th ed. Washington: National Academies Press; 2011.
Bai Z, Shi Y, Wang J, Qiu L, Teng G, Zhang F, Yang X. Multi-modality imaging-monitored creation of rat orthotopic pancreatic head cancer with obstructive jaundice. Oncotarget. 2017;8:54277–84.
Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53 R172H and Kras G12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469–83.
Stokes WS. Humane endpoints for laboratory animals used in regulatory testing. ILAR J. 2002;43:S31–8.
Caroline AS, Wayne SR, Kevin WE. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671.
Eresen A, Hafsa NE, Alic L, Birch SM, Griffin JF, Kornegay JN, Ji JX. Muscle percentage index as a marker of disease severity in golden retriever muscular dystrophy. Muscle Nerve. 2019;60:621–8.
Li Y, Eresen A, Lu Y, Yang J, Shangguan J, Velichko Y, Yaghmai V, Zhang Z. Radiomics signature for the preoperative assessment of stage in advanced colon cancer. Am J Cancer Res. 2019;9:1429.
Kim B, Kim J, Ahn S, Joo I, Choi S-Y, Park S, Han J. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis. Eur Radiol. 2019;29:362–72.
Choi M, Lee Y, Yoon S, Choi J-I, Jung S, Rha S. MRI of pancreatic ductal adenocarcinoma: texture analysis of T2-weighted images for predicting long-term outcome. Abdom Radiol. 2019;44:122–30.
Woodruff H, Blé FX, Jochens A, Leijenaar RTH, Ibrahim A, Brindle KM, Heinzmann K, McIntyre DJO, Lambin P. EP-2102: correlating MRI radiomics with biology during therapy in cancer models: a tool for drug development? Radiother Oncol. 2018;127:S1155–6.
Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. J Gastrointest Oncol. 2017;8:127.